Steady-state and dynamic MR angiography with MS-325: initial experience in humans

Area of Science:

• Radiology
• Medical Imaging
• Pharmacology

Background:

• Magnetic Resonance (MR) angiography is crucial for visualizing vascular structures.
• Developing effective blood-pool contrast agents enhances image quality and diagnostic accuracy.
• MS-325 is a novel gadolinium chelate designed for MR angiography applications.

Purpose of the Study:

• To assess the imaging performance of MS-325 for MR angiography.
• To evaluate patient tolerance of MS-325 during MR angiography procedures.
• To compare MS-325 enhanced imaging with conventional 2D Time-of-Flight (TOF) MR angiography.

Main Methods:

• A phase I clinical trial involving seven healthy volunteers.
• Intravenous injection of 0.05 mmol/kg MS-325.
• Acquisition of dynamic and steady-state 3D gradient-echo MR angiograms at multiple time points post-injection.
• Quantitative analysis of signal-to-noise ratio (S/N) and contrast-to-noise ratio (C/N), alongside qualitative image quality ranking.

Main Results:

• MS-325 was well-tolerated by all volunteers.
• Intense vascular signal enhancement was observed.
• Steady-state postcontrast images showed statistically significant higher image quality compared to 2D TOF.
• Mean peripheral arterial contrast-to-noise ratio (C/N) was significantly improved with MS-325.

Conclusions:

• MS-325 provides excellent vascular and selective arterial enhancement in dynamic MR angiography.
• The agent's long blood residence time facilitates high-resolution steady-state imaging of both arteries and veins.
• MS-325 represents a promising contrast agent for advanced MR angiography.